Achieve Life Sciences is preparing for a second NDA resubmission to the FDA after resolving previous manufacturing problems that caused a setback. The issues were related to manufacturing, not the drug's safety or efficacy, supported by two successful Phase 3 trials and over 1,500 patient exposures. The company is financially strong with $188 million in cash, enough to support the resubmission and initial product launch. Key risks include timely FDA acceptance and execution, with potential growth from expanding into vaping cessation treatments.
Achieve Life Sciences is the subject of this update, with Pluang providing health-sector market context. As of Sep 23, 2026 22:11 WIB, 26 of 100 priced health-sector US stocks rose while 72 fell. Notable movers include Summit Therapeutics Inc (SMMT) at USD 16.53 with a 3.45% decline and ClearPoint Neuro Inc (CLPT) at USD 15.29 with 100% sell order activity on Pluang.
Jefferies analysts set a new price target of $435 for General Electric Aerospace, implying a 35% upside from its current price of around $321. GE Aerospace's strong position is supported by a $170 billion commercial services backlog and 80,000 aircra...
BNP Paribas lowered its price target for PepsiCo from $183 to $161 on September 23, 2026, due to ongoing demand challenges in North America. Despite the cut, the firm maintained an Outperform rating, indicating confidence in the stock's potential. Th...
Celldex Therapeutics saw its price target raised from $70 to $88 by Leerink Partners following successful Phase III trial results for its drug barzolvolimab treating chronic spontaneous urticaria (CSU). The trials met all primary endpoints, showing l...
Ero Copper, a major copper producer, shows stock volatility between $16.88 and $40.83 over the past year. Analyst firm CIBC maintained a "Neutral" rating but increased the price target to C$56.00, reflecting optimism about the company's long-term gro...
Cintas Corporation posted robust first-quarter results, surpassing analyst expectations with earnings per share of $1.39 and revenue of $3.01 billion, a 10.9% increase year-over-year. The company's organic revenue growth was 8.9%, reflecting solid bu...
